T uberculosis (TB) management in the United States has evol ved during the past 3 decades to include a clear and decisive plan of action to eliminate active TB infection. Despite successful measures to decrease the incidence of active TB in the United States , occupational health professionals continue to handle an array of issues surrounding this disease .
Targeted identification, treatment, and elimination of TB for high risk groups-including health care workers-is the primary aim of employee or occupational health departments. This objective generates the need for clear and current policy for effective TB control. Tuberculosis management issues that continue to fuel discussion and affect practice guidelines in the hospital occupational health setting include: • The efficacy and problems created with two step testing in the health care environment. • The evolution of latent TB infection (LTBI) treatment from a historical perspective, and its affect on CUTrent TB management.
BACKGROUND
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis, an organism that pri-
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marily affects the lungs. The disease is transmitted from person to person via air droplet nuclei from individuals with active TB infection . "Active TB" refers to individuals who have clinical symptom s associated with the disease, positive chest radiographic evidence consistent with active TB, and identification of M. tuberculosis from sputum cultures or by DNA probe (Chesnutt, 2000) .
Unlike active TB, LTBI refers to individuals exposed to M. tuberculosis without evidence of active disease on chest x-ray or sputum studies. An immunocompetent immune system normally attacks TB bacteria and prevents it from growing. Individuals with LTBI do not have clinical symptoms of disease and are not considered contagious to others (Centers for Disease Control and Prevention [CDC], 2001). Individuals diagnosed with LTBI have a 10% lifetime risk of developing active disease-5% within the first 2 years post-exposure, and the remaining 5% for the duration of a lifetime (Atlanta Tuberculosis Prevention Coalition, 2001).
DIAGNOSIS AND TWO STEP TESTING
The diagnosis of LTBI is crucial for an effective occupational health TB control program. Employee health departments must ensure high risk employees in the hospital setting receive appropriate purified protein derivative (PPD) testing aimed at identifying TB infection in either its active or latent form. The CDC currently recommends health care work-ers receive two step PPD testing prior to initiation of periodic tuberculin screening (CDC, 1994) .
Two step testing involves administering two Mantoux tuberculin skin tests at least I week apart, but not to exceed 12 months in duration. Two step testing is based on the idea that a waning cell mediated response will produce an initial negative PPD reaction, but simultaneously stimulates anamnestic immune recall. Administration of the second skin test, at least I week to I year after the first skin test, creates a reaction of at least 6 millimeters of induration to be considered positive (Reichman , 2002) . In most health care settings, a reaction of 10 millimeters or greater is considered positive for health care workers without additional risk factors (CDC, 2000) .
Two step PPD testing of new employees who have not received a PPD skin test in the past year plays a fundamental role in identifying true TB conversions by helping ensure LTBI is not masked by a waning immune system. Sepkowitz, (200 I) contends that with the two step PPD theory, after health care workers receive initial negative two step testing and are subsequently periodically tested 6 to 12 months later, the booster phenomenon, ideally, plays a minimal role in confounding the results of PPD testing and leads to tighter TB control within the health care environment.
The booster phenomenon produces positive reactions on repeat PPD testing not specific to M. tuber-culosis exposure, thus complicating interpretation of PPD test results in some instances. Positive reactions are commonly seen in individuals 55 and older, individuals with a history of bacille Calmette Guerin (BCG) vaccine, and exposure to types of Mycobacterium other than tuberculosis. The booster phenomenon was demonstrated in a CDC study of healthy health care workers receiving serial PPD testing to the third to fourth test. In this study, an unanticipated number of individuals had positive PPD results (Sepkowitz, 2001 ) .
An argument has been made that small reactions of 5 to 9 millimeters of induration in health care workers may be caused by boosting. Periodic testing, commonly conducted on an annual basis in hospitals, may further enhance the boosting phenomenon, giving rise to misdiagnosed tuberculin conversion (Menzies, 2(02) .
Because two step testing is not specific for exposure to M. tuberculosis, the clinician may at times be faced with a decision making dilemma. For example, a health care worker with small reactions between 5 and 9 millimeters of induration on initial two step PPD testing has subsequent conversion to 10 millimeters on periodic testing 6 to l2 months later. This person has minimal client contact and no known exposure s to individuals with active TB. Should this individual be considered a true conversion and treated for LTBI? In ambiguous situations, the clinician should not only follow CDC practice guidelines, but also evaluate subjective and objective data related to exposure to possible TB source s, and consider the benefit versus the risk of LTBI treatment to determine appropriate management.
TREATMENT
Latent TB infection treatment, formerly referred to as "chemoprophylaxis" and "preventive therapy," has been a perplexing and continually changing issue. Occupational health departments must ensure LTBI treatment protocols follow current guidelines as outlined by the CDC, as well as be aware of changes in practice protocols based on rep-DECEMBER 2002, VOL. 50, NO. 12 Clinical Rounds: Hospital link utable research findings . The goal of "staying current" requires a careful, detailed, and frequent examination of the latest data and recommendations related to LTBI treatment.
Historical Roots
The historical roots of LTBI treatment date back to 1965 when the American Thoracic Society (ATS) first recommended the use of isoniazid (INH) for individuals with recent PPD conversions and previously untreated TB. By 1967, the ATS and the Public Health Service expanded INH recommendations to include individuals with skin tests greater than or equal to 10 millimeters, thus, leading to a vast increase in the use of the medication. The risks of INH were realized after a TB outbreak on Capitol Hill in 1970. Thousands of people were started on INH, with 19 individuals developing clinical signs of liver failure and 2 dying of hepatic failure. This event led to research investigations aimed to better understand the risk of hepatitis related to INH treatment (CDC, 2000) .
By 1974, INH recommendations were modified . Low risk individuals older than 35 were not considered candidates for INH treatment. This particular guideline created a great deal of controver sy because the true risk to individuals younger than 35 was not well understood--evoking debate related to the overall risk versus benefit of INH treatment. The impact of excluding low risk individuals older than 35 caused ambiguity and doubt about the safety of INH, which in tum led to a significant decline in use of the medication.
In 1983, INH treatment recommendations were revised to include individuals older than 35. The guidelines further contended that individuals older than 35, and those with other risk factors associated with hepatotoxicity should receive routine clinical and laboratory monitoring. The effect of expanding the recommended age for INH treatment did not generate a great increase in use and compliance with the medication.
Many individuals continued to perceive the drug as potentially harmful and the long duration of treatment laboriou s, leading to the introduction of alternative drug therapy such as rifampin (RIF) for TB treatment. Furthermore, the appearance of HIV and TB co-infection generated further research and led to additional short course treatment recommendations (CDC, 2000) .
By 1998, rifampin (RIF) and pyrazinamide (PZA ) combination therapy for a duration of 2 months became available for HIV negative clients. This therapy was deemed as an acceptable alternative to INH therapy (Reichman, 2002) .
Current Recommendations
As LTBI medication treatment choices expanded, health care professionals gained a greater understanding of INH efficacy. In 2000, the CDC proposed that the duration of INH treatment for health care workers with skin tests greater than or equal to 10 millimeters of induration without other risk factors, should be increased from 6 to 9 months. Research studies indicated a maximal benefit of INH could be achieved at 9 months compared to 6 months, and INH treatment for 12 months was minimally beneficial (CDC, 2000) .
Prior to beginning LTBI treatment, employees should receive a clinical evaluation including a physical examination with emphasis on objective data associated with hepatitis and discussion of medication side effects. Baseline laboratory monitoring to include asparate aminotransferase or alanine aminotransferase may be offered at baseline for individuals without risk factors, but is not routinely recommended . Unless baseline testing is abnormal or the clinical history and examination reveal an increased risk of hepatic injury, routine laboratory testing during therapy for LTBI is not generally necessary (CDC, 2(00).
In 200 I, evidence related to the safety of the 2 month regimen of RIF -PZA came into question. Twenty one cases of hepatic injury related to this therapy were reported to the CDC . Sixteen individuals recovered fully, while the remaining 5 died of liver failure. These findings prompted modification to CDC 2000 guidelines related to the 2 month RIF-PZA regimen.
The ATS and CDC, with support of the Infectious Diseases Society of America, currently recommend the 2 month RIF-PZA regimen should be used with caution, and 9 months of daily INH should remain the preferred treatment for LTBI. However, closer clinical and laboratory monitoring to include serum aminotransferase and bilirubin at baseline and again at 2, 4, and 6 weeks of treatment is needed. Finally, CDC emphasizes the current data are preliminary and further investigation is needed to fully quantify the true risk for liver injury (CDC, 200 I).
CONCLUSION
Advances in TB management have been extraordinary and have led to a substantial decline in rates of active TB in the United States. However,changes in TB management continue to evolve, Clinical Rounds: Hospital Link and it is imperative for occupational health professionals to remain current with guidelines and criteria for practice. Continued awareness related to changes in LTBI diagnosis and treatment management is crucial. When vague and subjective decision making is required, occupational health professionals should be comfortable in accessing resources, consulting with others, and periodically reviewing current research data to aid in determining appropriate management.
